

Oct 2006 (HHS Reference No. E-190-2003/0-US-04).

*Licensing Status:* Available for exclusive or nonexclusive licensing.

*Licensing Contact:* Tara Kirby, Ph.D.; 301/435-4426; [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov).

### Methods for Assaying Hair Follicle Growth and Development

*Description of Technology:* Methods of culturing functionally-intact hair follicles in a collagen matrix are useful for screening baldness treatments and the quantification and study of the effects of agents on hair follicle growth. This technology describes techniques for measuring cell proliferation or for measuring secretion of collagenolytic factors, incorporating a three-dimensional hair follicle culture system. Collagenolytic activity is essential for downgrowth of hair follicles during anagen. One described method measures the effects of a growth factor or pharmaceutical compound on cell proliferation, utilizing the incorporation of tritiated thymidine into DNA of cultured hair follicles. Also described is a method to measure the effect of growth factors on the release of collagenolytic factors, utilizing tritiated collagen or a fluorescent marker.

*Applications:* Assays for screening drugs or growth factors that may stimulate hair growth; Assays measuring the DNA synthesis and collagenase-secreting activity of hair follicles.

*Market:* An estimated 40 million men and 20 million women suffer from hair loss; The market size for hair restoration procedures in the United States is approximately \$800 million.

*Inventor:* Stuart H. Yuspa (NCI).

#### Publications:

1. G Rogers, N Martinet, P Steinert, P Wynn, D Roop, A Kilkenny, D Morgan, SH Yuspa. Cultivation of murine hair follicles as organoids in a collagen matrix. *J Invest Dermatol.* 1987 Oct;89(4):369-379.

2. W Weinberg, P Brown, WG Stetler-Stevenson, SH Yuspa, Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. *Differentiation.* 1990 Dec;45(3):168-178.

*Patent Status:* U.S. Patent No. 5,616,471 issued 01 Apr 1997 (HHS Reference No. E-213-1987/1-US-01).

*Licensing Status:* Available for nonexclusive licensing.

*Licensing Contact:* Tara Kirby, Ph.D.; 301/435-4426; [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov).

Dated: January 9, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-626 Filed 1-17-07; 8:45 am]

**BILLING CODE 4140-01-P**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Initial Review Group, Subcommittee G—Education.

*Date:* February 6-7, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Washington Court Hotel, 525 New Jersey Avenue, NW., Washington, DC 20001.

*Contact Person:* Sonya Roberson, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8109, Bethesda, MD 20892, 301-594-1182, [roberson@mail.nih.gov](mailto:roberson@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 9, 2007.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-178 Filed 1-17-07; 8:45 am]

**BILLING CODE 4140-01-M**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Advisory Council.

*Date:* February 14, 2007.

*Open:* 8 a.m. to 12 p.m.

*Agenda:* Discussion of program policies and issues.

*Place:* National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

*Closed:* 1 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

*Contact Person:* Stephen Mockrin, PhD, Director, Division of Extramural Research Activities, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7100, Bethesda, MD 20892, (301) 435-0260, [mockrins@nhlbi.nih.gov](mailto:mockrins@nhlbi.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a